Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States

Value in Health

Volumn 12, Issue 4, 2009, Pages 481-488

  Lang, Kathleen ^b   Marciniak, Martin D ^a   Faries, Douglas ^a   Stokes, Michael ^b   Buesching, Don ^a   Earle, Craig ^c   Treat, Joseph ^a   Babineaux, Steve ^a   Morissette, Nathalie ^b   Thompson, David ^b  

^a ELI LILLY AND COMPANY   (United States)

^b 13 Innovus ^*  (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cost analysis; Gemcitabine; Longitudinal analysis; Lung cancer; Pharmacoeconomics

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; VINBLASTINE;

AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGISTRY; DEHYDRATION; DELIRIUM; DOUBLET CHEMOTHERAPY; FEMALE; FEVER; HEALTH CARE COST; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICARE; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; HEALTH CARE COSTS; HUMANS; LUNG NEOPLASMS; MALE; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; TAXOIDS; UNITED STATES;

EID: 66249144997     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00472.x     Document Type: Article

References (20)

1. Ettinger DS, Bepler G, Bueno R, et al. Non-small cell lung cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006 4 : 548 82.
2. Weick JK, Crowley J, Natale RB, et al. A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1991 9 : 1157 62.
3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy for non-small cell lung cancer. The Cochrane Library, 2000, Issue 2. Available from: http://gateway.ut.ovid.com.proxy.medlib.iupui.edu/gw1/ovidweb.cgi [Accessed June 11, 2007].
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002 346 : 92 8.
5. Treat J, Belani CP, Edelman MJ, et al. A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC): update of the alpha oncology trial (A1-99002L). J Clin Oncol 2005 23 : 7025.
6. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006 24 : 3187 205.
7. Hillner BE, McDonald K, Desch CE, et al. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort. J Clin Oncol 1998 16 : 1420 4.
8. Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from Surveillance, Epidemiology and End Results-Medicare. J Clin Oncol 2004 22 : 4971 8.
9. US Food and Drug Administration. Center for drug evaluation and research. Drugs@FDA. FDA Approved Drug Products. Available from: http://www.accessdata. fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Search-Drug-Name [Accessed May 17, 2007].
10. National Cancer Institute (NCI). SEER-Medicare Publications. 2005. Available from: http://healthservices.cancer.gov/seermedicare/overview/ publications.html [Accessed June 11, 2007].
11. Lin DY, Feur EJ, Etzioni R, Wax Y. Estimating medical cost from incomplete followup data. Biometrics 1997 53 : 419 34.
12. Zhu B, Tunis S, Zhao Z, et al. Service utilization and costs of olanzapine versus divalproex for acute mania: results from a randomized 47 week clinical trial. Curr Med Res Opin 2005 21 : 555 64.
13. Diehr P, Yanex D, Ash A, et al. Methods for analyzing health care utilization and costs. Annu Rev Public Health 1999 20 : 125 44.
14. Good P. Permutation Tests: A Practical Guide to Resampling Methods for Testing Hypotheses. New York, NY : Springer-Verlag, 2000.
15. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984 79 : 516 24.
16. Potosky AL, Saxman S, Wallace RB, Lynch CF. Population variation in the initial treatment of non-small-cell lung cancer. J Clin Oncol 2004 22 : 3261 8.
17. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest 2000 117 : 1239 46.
18. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006 28 : 1779 802.
19. Cascone T, Troiani T, Morelli MP, et al. Antiangiogenic drugs in non-small cell lung cancer treatment. Curr Opin Oncol 2006 18 : 151 5.
20. Kris MG. How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care. Oncologist 2005 10 (Suppl. 2 S23 9.